“The only relevant test of the validity of a hypothesis is comparison of prediction with experience.”

—Milton Friedman

Let’s face it. We love clinical prediction rules that forecast outcomes in cardiovascular medicine. Our clinical armamentarium is suffused with a variety of scores that seek to predict unique outcomes such as the Framingham risk score for future ischemic events, the Congestive Heart Failure, Hypertension, Age ≥75, Diabetes Mellitus, and Prior Stroke or Transient Ischemic Attack (CHADS2) score to ascertain the risk of neurological events in atrial fibrillation, or clinical decision rules to exclude acute coronary syndromes in patients presenting to the emergency department. Generally, for a prediction rule to be successfully inserted into our clinical lexicon, it should be highly relevant, easy to use, and exercise sufficient discrimination between extremes to allow for deployment of decisional strategies. This frequently requires an artificial reductionism of the clinical outcome of interest into yes or no categorical variables. Often, such an oversimplification of an otherwise complex outcome variable can render it to be less informative.

Clinical Experience With Tailored Immunosuppression

Using heuristics (experience-based techniques for problem solving), seasoned cardiac transplantation clinicians have long recognized these very variables to be necessary for posttransplant risk stratification, and the evident disparity in clinical outcomes among these distinct cohorts has led to performance of targeted intervention studies in these patient subsets in an effort to improve overall outcome. In 2002, we demonstrated that the combination of tacrolimus and mycophenolate mofetil was superior to one that used cyclosporine as the calcineurin inhibitor in black heart transplant recipients. This investigation found a significant reduction in hemodynamically compromising rejection and consequent enhanced survival. In a lower risk population (largely men of white descent) Baran and colleagues demonstrated that tailored monotherapy with tacrolimus is feasible and safe when compared with dual drug immunosuppression, and did not diminish outcomes significantly, thus suggesting that tailored therapy was possible in such populations. Therefore, the contention that one could use a risk prediction rule to risk stratify heart transplant recipients and test tailored immunosuppression strategies is not a far-fetched one. In that sense, Kilic and colleagues have been rather astute in taking these known risk markers and putting them together in the form of this prediction rule algorithm. However, it would appear that the best discrimination achieved at the highest score category is no more than a mere coin flip for a patient (50.7%). Why might this be so?

Era Effects in Transplant Recipient Management

The decade of 1998 to 2008 represented an era of intense activity characterized by several fundamental shifts in our management of advanced heart failure and transplant patients. In 1998, evidence that mycophenolate mofetil was associated with a survival benefit on the heels of diminishing hemodynamically compromising rejection episodes was greeted positively and led to it gradually supplanting azathioprine as the adjunctive immunosuppression of choice. In tandem with this shift, tacrolimus became the more dominant calcineurin inhibitor for use instead of cyclosporine. Investigations that studied different regimens of immunosuppression combinations suggested that the best risk–benefit ratio was achieved by the combination of tacrolimus and mycophenolatemofetil.
Although induction agents such as monoclonal antibodies supplanted the older polyclonal induction agent Muromonab-CD3 (Orthoclone OKT3), evidence for a benefit was less forthcoming.\(^\text{10,11}\) Another important shift in the recipient characteristic was the slow but definite growth of mechanical circulatory support as a bridge to transplantation and recognition that the presence of this durable device resulted in distinct immunologic perturbations in the host. Indeed, by 2009, a third of all recipients undergoing transplantation were so bridged under support with a durable mechanical device.\(^\text{12}\) Because of the limitations of registry-based databases, Kilic and colleagues\(^\text{4}\) could not control for the evolving use of immunosuppressants, the presence or absence of inclusion of patients within the rigid frame work of clinical trials, and targeted tailoring of immunosuppression by some centers for the elderly or recognized high risk groups.

**Changing Epidemiology of Cardiac Allograft Rejection**

Evidence has been forthcoming that the evolution of immunosuppression in the last decade has, in tandem, been associated with a changing epidemiology of rejection-based outcomes during the recent decade from analyses embedded within the International Society for Heart and Lung Transplantation registry,\(^\text{12}\) which includes the United Network for Organ Sharing database and also more broadly represents the state of transplantation across the globe. Among patients who underwent heart transplants between April 1994 and 2000, the need for hospitalization for treatment of rejection within 1 and 5 years after transplant was 41% and 59%, respectively. In contradistinction, between 2001 and June 2009, hospitalization for rejection treatment decreased to 26% at 1 year and 44% within 5 years after transplant. This changing epidemiology raises some doubt about the performance of the proposed prediction rule in more contemporary cohorts characterized by an older recipient age, exposure to novel immunosuppressants, and a greater bridging with mechanical circulatory support devices which may distinctly alter the immunologic milieu but with acceptable rejection-based outcomes.\(^\text{13,14}\)

**Observations From Other Registry Analyses**

In a separate registry study that consisted of 10 131 patients from 29 institutions in the Cardiac Transplant Research Database (n=7368, from 1990–2008) and 32 institutions in the Pediatric Heart Transplant Study (n=2763, from 1993– 2008), George and colleagues\(^\text{15}\) estimated the probabilities of death resulting from rejection and infection with a parametric time-related model that was specifically adjusted for sex, ethnicity, date of transplant, and age. These investigators discovered that death resulting from rejection at 5 years was highest among those transplanted at 10 to 30 years of age and lowest in those transplanted at >60 years of age. Death resulting from infection at 5 years was highest among patients >60 years of age. In this registry analysis, recipient risk markers for death for rejection were age, female sex, black race, and transplant date. Importantly, modeling with respect to age at time of transplant showed an inverse relationship between infection and rejection death. Among patients transplanted at >60 years of age, there was a steep increase in infection-related deaths and a decrease in rejection deaths. Risk for rejection was highest among young adults 10 to 30 years of age at time of transplant, particularly for black females. Thus, the variables included by Kilic and colleagues\(^\text{4}\) appear to be those well characterized and confirmed in separate well-conducted registry-based analyses with evidence of broad applicability. Even if the risk variables included in the scoring system to derive the prediction rule are robust, an even more important issue resides in the clinical relevance of the rejection-based outcome of primary interest.

**Diverse Phenotypes of Cardiac Allograft Rejection**

To denote rejection as a simplistic dichotomous variable is a fallacy that grossly limits the understanding of the diverse phenotype represented by this prognostically relevant end point. Two distinct forms of cardiac allograft rejection are recognized, including acute cellular rejection (ACR) and antibody-mediated rejection (AMR), which can sometimes coexist. Immunologically, ACR is typically a T cell–mediated assault on the donor allograft tissue and occurs most commonly early, within the first 6 months of transplantation with a declining incidence thereafter. The histopathology of cellular rejection is notable for lymphocytic infiltrates, which in mild cases of rejection are localized to the perivascular regions, and in severe cases lymphocyte infiltration progresses diffusely into the cardiac interstitium. In late stages of severe ACR, multinucleated cells like macrophages, neutrophils, and eosinophils are observed with associated evidence of myocyte injury, intramyocardial hemorrhage, and myocyte necrosis.\(^\text{16}\) This form of rejection can remain clinically silent and histologically overt or progress to evidence of cardiac allograft failure. Thus, treatment and significance can be fairly diverse, with the greatest variability in treatment threshold for asymptomatic forms of ACR. Some centers treat all such episodes, even those that are histologically graded as mild, whereas other centers have established nontreatment observational strategies with repeat endomyocardial biopsies in the setting of mild rejection, because there is recognition that a large majority of such episodes resolve spontaneously with longitudinal observation.\(^\text{17}\) This variability calls into question the notion of the informative significance of any treated rejection from multiple centers when more details about the gravity of such episodes are unavailable. For instance, how did the center define treatment of rejection? Was it a simple up titration of the calcineurin inhibitor and antiproliferative adjunctive agents? Was it augmentation in corticosteroids? Were the corticosteroids administered orally for a short duration or intravenously in high doses? Was the patient hospitalized for such therapy or treated as an outpatient? Did the patient experience hemodynamic compromise of the cardiac allograft or was cardiac function preserved? Did the rejection episode resolve or was it persistent at milder grades? These issues cannot be answered adequately by the simplistic dichotomous outcome variable as studied by Kilic and colleagues,\(^\text{4}\) and therefore clinical decision comfort around the construct of this prediction rule is weak at best.
Emergence and Recognition of Antibody-Mediated Rejection

The recent recognition and standardization of AMR represents the culmination of an evolving concept of a distinct form of rejection that was not adequately characterized in the cohort studied from 1998 to 2008. This form of rejection is immunologically described as a noncellular antibody-driven phenomenon that was debated for years and only recently officially recognized with equal pathological rigor as ACR. Only recently has the transplant pathology community developed a standardized nomenclature for this entity because of the recognition that this phenotype of rejection is being recognized more often in current patient cohorts whereas potent novel immunosuppression has achieved a reduction in the incidence of significant ACR. AMR is a form of rejection associated with cardiac allograft arteriolar vasculitis and a pattern of immunopathologic findings of immunoglobulin deposition and complement fixation on immunofluorescence, along with histopathologic findings of endothelial swelling and interstitial edema on routine light microscopy. AMR is associated with decreased cardiac allograft survival compared with ACR and seminally characterized by the emergence of donor-specific antibodies in the peripheral circulation that are thought to bind to the allograft, thereby propagating the reaction of AMR. Commonly, this phenotype leads to acute allograft dysfunction and increases the risk for cardiac allograft vasculopathy, even when the phenomenon is initially restricted to the histology of the allograft without overt signs of cardiac dysfunction. The reported incidence of noncellular rejection or AMR has been variable depending on clinical and histopathology criteria used, with an estimated incidence of 8% to 20%. Strikingly, treatment paradigms for AMR are still not clearly established and outcomes remain poor, especially for AMR associated with allograft dysfunction. Of the variables identified in the Kilic study, black race and female sex have been associated with an increased propensity for AMR, especially in the setting of a positive donor-specific cross match and elevated circulating donor-directed antibodies.

Potential Clinical Applications of Prediction Rules

Even then, what might the potential applications of such rejection-based prediction rules be in cardiac transplantation? Although 1-year outcomes in cardiac transplantation have seen improvements in survival to >90%, 10-year survival has not improved in tandem with these early advances. We now recognize that early events in the posttransplantation period, particularly rejection, continue to exact a late toll leading to selective attrition of survival by the development of cardiac allograft vasculopathy, renal dysfunction, and malignancy. Prediction rules may allow discrimination, albeit crude, to develop target populations that are at risk for poor late survival, and this cohort may be most amenable to active study surrounding therapeutic targets that concentrate on reducing metabolic complications, tailoring of immunosuppression to avoid overimmunosuppression, and its sequelae such as renal failure and malignancy. As genomic, transcriptomic, and protein-based predictive biomarkers become available, it would be ideal to identify the biosignatures that mechanistically serve as the underpinnings that identify and predict risk of adverse immunologic outcomes, allowing a much better refinement of predictive risk scores that eliminate the classical individual heterogeneity of outcome risk. It may well be that a combined biomarker–clinical phenotype risk prediction model may provide greater clinical decision support.

In summary, algorithmic prediction rules are important guides to more rational thinking but not designed to replace heuristics. As B.F. Skinner eloquently said, “The real problem is not whether machines think but whether men do.”

Disclosures

Dr Mehra serves as Chairman of the Data Safety and Monitoring Board for the Randomized Evaluation of VAD InterVention before Inotropic Therapy (REVIVE-IT) Study, funded by the National Heart, Lung, and Blood Institute. In addition he reports consulting income from St Jude’s, Medtronic, Abbott Vascular, Johnson and Johnson, and the American Board of Internal Medicine (all <$10,000, modest). Dr Mehra is an Officer of the International Society for Heart and Lung Transplantation and Editor-in-Chief of the Journal of Heart and Lung Transplantation.

References


Key Words: Editorials forecasting heart transplantation outcome studies rejection heart transplants.
Balancing the Tightrope of Cardiac Allograft Rejection: Equations or Experience?
Mandeep R. Mehra

_Circulation_. 2012;125:2971-2974; originally published online May 25, 2012;
doi: 10.1161/CIRCULATIONAHA.112.113019

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/125/24/2971

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/